German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.

Germany's Merck KGaA on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign ...

The group lifted its full-year guidance for growth in underlying earnings, due to better prospects for its life-sciences and ...

Net profit rose in the second quarter compared to the same period of the previous year for German science and technology ...

Investing.com -- Merck KGaA (ETR: MRCG ) reported second quarter earnings that missed analyst expectations, with EBITDA pre falling 3.1% to €1.5 billion, approximately 4% below consensus estimates.

Germany’s Merck KGaA (MRK: DE) has reported second quarter earnings that missed analyst expectations. The life sciences company’s earnings before interest, taxes, depreciation and amortization (EBITDA ...

Merck KGaA is the world's largest still-operating pharma and healthcare company, with a 300+ year history. It has absolutely stellar fundamentals, and what risks do exist are well-covered by the ...

Prof. Dr. Frank Stangenberg Haverkamp, Chairman of Merck Foundation BOT shared,“It was a great pleasure to meet H.E. Senator OLUREMI TINUBU, CON, The First Lady of the Federal Republic of Nigeria , ...

Merck KGaA is the world's largest still-operating pharma and healthcare company, with a 300+ year history. It has absolutely stellar fundamentals, and what risks do exist are well-covered by the ...

FRANKFURT, March 7 (Reuters) - Merck KGaA (MRCG.DE) forecast a return to modest operating earnings growth this year but only when adjusted for currency headwinds, citing a gradual recovery in ...

Aside from ongoing debt servicing requirements, Merck KGaA has few demands on its free cash flow (EUR 3 billion in 2022) other than its common stock dividend (EUR 0.2 billion in 2022) and ongoing ...

Senator Dr. Rasha Kelej emphasized the critical role that journalists, media professionals, and storytellers play in shaping ...